Biokine Therapeutics Announces Issuance of Japan Patent covering the composition and use of novel chemokine binding polypeptides
capable of inhibiting the course of autoimmunity, inflammation, and cancer (BKT130 project).
Biokine Therapeutics Announces Issuance of Japan Patent covering the composition and use of novel chemokine binding polypeptides
capable of inhibiting the course of autoimmunity, inflammation, and cancer (BKT130 project).